is this you? Claim your profile.
is this you? Claim your profile.
Vice President, Analytical and Pharmaceutical Sciences
HQ Phone:  (520) 219-2900
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
2005 E. Innovation Park Drive
Formed in 1992, IBC is recognized as one of the first biotech companies in Arizona. President and founder Robert Green saw it as an opportunity. "It was a chance for us to utilize the resources of a community with a first-class research institution (the Univer... more.
President and Chief Executive Officer
Vice President, Research and Development
Director, Quality Labs
Director, Research and Development
Vice President, Advanced Analytical Sciences
Director of Quality Control
Senior Staff Scientist and Head of the Mass Spectrometry Group In the Research and Development Department
Mississippi State Crime Laboratory
Analytical Center of Excellence
Jackson State University
Jackson State University
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill , NC
Earl White, Ph.D., President and CEO directs MDx BioAnalytical laboratory research program.
Dr. White was Vice President, Analytical and Pharmaceutical Sciences for Integrated Biomolecule Corporation from July 2007 to November, 2008. Previously, he served as Vice President of Advance Analytical Sciences for Large Scale Biology Corp (LSBC) and Predictive Diagnostics, Inc. (PDI) whose parent company was LSBC, a publicly-traded company. Dr. White joined LSBC in 1998 as a Senior Scientist and established the Analytical Center of Excellence. A year later he was promoted to Director of Advanced Analytical Resources and served as Director of Quality Control for LSBC's Non-Hodgkin's Lymphoma (NHL) cancer vaccines program, the Company's first clinical product candidate. In 2002, he was appointed Vice President, Advanced Analytical Sciences. Prior to joining LSBC, Dr. White was Sr. Staff Scientist and Head of the Mass Spectrometry Group in the Research and Development Department of R.J. Reynolds Tobacco Company from 1985-1998. Dr. White received the B.S. and M.S degrees in chemistry from Jackson State University in Jackson, MS and a Ph.D. degree in analytical chemistry from the University of North Carolina at Chapel Hill, NC where he specialized in mass spectrometry. Almost all shares and options are in the hands of Earl and Dorothy White.
Earl L. White, Ph.D.Vice President of Analytical & Pharmaceutical Sciences Earl received his Ph.D. in Analytical Chemistry - Mass Spectrometry from the University of North Carolina at Chapel Hill and an M.S. in Organic & Analytical Chemistry from Jackson State University.He has published more than 23 peer-reviewed papers and authored more than 37 abstracts and presentations.Prior to joining IBC, he was Vice President, Advanced Analytical Sciences and Director, Quality Control at Large Scale Biology Corporation and its subsidiary, Predictive Diagnostics, Inc.At Large Scale and PDI he assisted with the successful completion of a Phase 1 Clinical Trial for a Non-Hodgkin's lymphoma vaccine and was a principal investigator in the development of the first patented in silico machine learning technologies and proprietary informatics tools for use with biological samples.
Al Petrillo/Special to The Explorer, Earl White, owner of MDx, operates an Agilent 5973N Gas Chromatograph-Mass Spectrometer system.
MDx BioAnalytical is built around the strength of the skills and experience of Earl White, Ph.D, who serves as president and CEO, and his wife, Dorothy, who is managing director. "We do almost everything that has to do with a pharmaceutical company getting its drug to market," Earl White said, "such as pre-clinical work, characterizing the molecule and stabilities studies to determine how long a drug will last." White said that MDx also performs pharmacokinetic studies, which examine how a drug behaves in the human body. "We use a contract research organization that does animal studies on the drug, generally using mice and rats, and then collects tissue samples that we analyze," White noted. In addition, MDx sets up release assays for pharmaceutical companies in which a drug has already been formulated and is ready for patient use. "In such a case there might be a clinical trial where we perform assays to determine the identity, purity and concentration of the drug to make sure it meets specifications," White said. White sees the company's second main focus as the one that has the potential to put MDx on the biotechnological map. "I helped develop an algorithm to search for biomarkers while I was with a company in California prior to coming to Tucson," White said. "We're in the process of getting access to that algorithm." Once MDx has that access, White said he can use it to find biomarkers that characterize a patient as diseased or non-diseased. "We also will be able to project how well a specific treatment might work," he added. "We've submitted for a National Institutes of Health Challenge grant and have formed consortiums with Arizona State University's Biomedical Infomatics Department and the Tufts University dental school in Boston." White said the algorithm can search biomarkers for any disease, including autoimmune diseases such as Sjogren's Syndrome and Alzheimer's disease. "It's also been used on multiple sclerosis, ovarian cancer in a study at UCLA, and for prostate and breast cancers," he said. Before starting MDx BioAnalytical, White served as vice president of analytical and pharmaceutical sciences at Integrated Biomolecule Corporation in Oro Valley. Integrated Biomolecule's lab space off Innovation Park Drive was purchased last November by Ventana Medical Systems, the Roche Holdings-owned diagnostics firm that stands directly across the street. IBC now operates out of other venues, while Ventana uses the lab for its own purposes. Prior to that, White was vice president of advanced analytical sciences for Large Scale Biology Corp., and its subsidiary, Predictive Diagnostics Inc. Before joining LSBC, he was senior staff scientist and head of the mass spectrometry group in R.J. Reynolds Tobacco Company's research and development department. He began his career as a forensic toxicologist with the Mississippi State Crime Laboratory. White holds bachelor of science and master of science degrees in chemistry from Jackson State University in Jackson, Miss., and a Ph.D in analytical chemistry from the University of North Carolina at Chapel Hill.
(July 22, 2008) Earl White of Integrated Biomolecule is a principal investigator and co-author of a paper detailing the use of the tobacco plant to grow an anti-cancer vaccine.
IBC will also gain Earl L. White, previously the managing director of PDI Analytical and vice president of analytical sciences for Large Scale Biology.
White will serve as IBC's vice president of analytical and pharmaceutical sciences.